If you've spent any time researching ayahuasca, psilocybin, or ketamine-assisted therapy lately, you've probably noticed something odd. The field used to feel like a whisper network — a friend of a friend who knew a curandero, a quiet retreat tucked into the Dutch countryside, a clinical trial you needed three referrals to enter. Now there are venture-backed startups, telehealth platforms, and biotech labs trying to engineer the next generation of compounds. The money has arrived. So have the spreadsheets.

For someone weighing whether to book a psychedelic retreat or try plant medicine for addiction, depression, or just the slow grind of feeling stuck, this matters. The companies getting funded right now will shape what's available to you in the next few years — the protocols, the prices, the credentialing of facilitators, even whether your insurance ever picks up the tab. So it's worth knowing who they are and what they're actually doing.

Here's a tour of seven companies that investors have flagged as movers in the space, plus some honest thoughts on what their existence means for people considering a real-life journey.

Why the Psychedelics Industry Suddenly Has VCs Circling

Analysts have thrown around forecasts that the psychedelic treatment market could eventually clear nine figures globally. Whether that number holds or not, the underlying logic is real: depression rates aren't dropping, SSRIs work for some people and fail others, addiction continues to gut families, and the existing mental-health system is buckling. Psychedelics — used carefully, with skilled support — have shown enough promise in clinical trials that smart capital wants in.

What that means in practice is a wave of startups doing very different things. Some are trying to design molecules. Some are training therapists. Some are building software for clinics. And a few are doing what humans have done for thousands of years — running retreats with master plants and trained facilitators, just with a website and a Stripe account attached.

The categories you'll see funded

• Drug development — labs creating novel compounds, including non-hallucinogenic analogs.
• Therapist training — programs credentialing the practitioners who will actually sit with patients.
• Clinical infrastructure — software, prescribing networks, and patient management tools.
• Integration support — apps and platforms for the days and weeks after a session.
• Retreats and facilitation — the in-person work, often legal in jurisdictions like the Netherlands, Jamaica, or Peru.

Seven Startups Worth Knowing About

Delix Therapeutics

Based in Boston and founded in 2019, Delix raised north of $100 million working on what they call psychoplastogens — compounds inspired by psychedelics but engineered to skip the trip. The idea is to capture the neuroplasticity benefits (the brain-rewiring part that seems to do a lot of the therapeutic work) without the six-hour experience of ego dissolution. Early animal research suggests these compounds may even reverse cortical atrophy.

Whether you find that exciting or vaguely depressing probably says a lot about your worldview. For people who can't take time off work, can't tolerate altered states, or have medical contraindications, a non-hallucinogenic option is genuinely important. For those who believe the mystical experience itself is the medicine, it's a harder sell.

Fluence

Out of Woodstock, New York, Fluence trains psychiatrists, therapists, and social workers in psychedelic-assisted therapy and integration. They raised a modest $3 million seed round, but their work matters disproportionately. The single biggest bottleneck for legal psychedelic therapy isn't the drugs — it's the people qualified to sit with you while you take them.

If you've ever wondered why finding a competent psychedelic-informed therapist feels harder than finding a unicorn, this is why. The training pipeline is tiny. Companies like Fluence are trying to fix that.

Homecoming

Toronto-based and only a few years old, Homecoming is a digital companion for the period before and after a psychedelic session. Think daily check-ins, journaling prompts, structured integration tasks, and a way for your therapist to see how you're actually doing between appointments.

This is the unsexy part of psychedelic work that almost everyone underestimates. The ceremony is loud and dramatic. Integration — the quiet weeks afterward when you're trying to actually change something about your life — is where the work really lands or doesn't.

Journey Clinical

New York-based Journey Clinical built a decentralized model for ketamine-assisted psychotherapy. Your existing therapist — the one who already knows your story — partners with their in-house medical team, who handles eligibility screening, prescribing, and clinical monitoring. You don't have to start over with a stranger to access the medicine.

This is one of the more elegant ideas in the space. Continuity of care matters enormously in trauma work, and the standard model of being shuffled to a separate ketamine clinic with a new provider has always felt clinically backwards.

Mindstate Design Labs

Pittsburgh-based and well-funded for a young company, Mindstate is using AI and biochemical data to predict what specific mental states a compound will produce. Their first program is aimed at recreating the empathogenic, MDMA-like state — the warm, connected, defenses-down feeling that has shown such promise for PTSD work.

It's ambitious and a little science-fiction. Whether they can actually predict subjective experience from molecular structure is an open question, but the team has impressed people who've looked under the hood.

Osmind

San Francisco-based Osmind is the software backbone for clinics offering ketamine and other psychedelic therapies. It helps practices run, but the long-term value is the data — outcomes data that could eventually convince insurers to cover these treatments, and research data that could refine protocols.

Boring on the surface. Probably consequential underneath.

Synthesis Institute

Amsterdam-based Synthesis has been around since 2018, running legal psilocybin retreats in the Netherlands and training facilitators. They've adopted a steward-ownership structure — meaning founders and investors are legally bound to the company's mission and social impact, not just returns. That's rare, and it tells you something about how the team is thinking.

For readers actually considering a retreat, Synthesis is one of the names that comes up most often in serious conversations about legal, well-organized psilocybin work in Europe.

What This Means If You're Considering a Retreat

Here's the honest part. None of these companies will sit with you at three in the morning when the medicine is asking you to look at something you've avoided your whole life. That work still happens between you, the plant, and whoever is holding the space.

What the industry buildout does change is access. More trained therapists. Better integration support. Clearer information about safety. More legitimate options between the extremes of underground ceremonies with strangers and waiting years for a clinical trial slot. If you're researching plant medicine for addiction recovery, depression, or trauma, the field you're entering today is more navigable than it was even two years ago.

A few things that haven't changed and probably won't:

• Reputable facilitators still matter more than any app or platform.
• Preparation in the weeks before a ceremony shapes the experience more than most people realize.
• Integration is where transformation either happens or evaporates.
• Plant medicine is not a shortcut. It's a tool, and a demanding one.

How to Actually Choose a Retreat in This New Landscape

Funding announcements are not the same as quality. A startup with $50 million in the bank can still run a mediocre program, and a small lineage-based retreat can offer the most profound experience of your life. When evaluating a retreat, the questions worth asking have less to do with branding and more to do with substance:

1. Who facilitates, and what's their actual training and lineage?
2. What does medical screening look like before they accept you?
3. What's the integration support — and is it included or sold separately?
4. How many participants per facilitator, and what's the supervision ratio overnight?
5. What's their protocol if someone has a difficult experience or a medical emergency?
6. Can you talk to past participants who aren't pre-selected testimonials?

If a retreat dodges those questions or answers them with marketing language, that tells you something. If they answer them specifically and without defensiveness, that tells you something else.

The psychedelic industry is having its moment, and that's mostly good news for people who need help. The molecules, the software, and the venture capital are all interesting — but the actual healing still happens in a room with a person who knows what they're doing. If exploring this further feels right, a curated range of ayahuasca, psilocybin, and plant-medicine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine isn't going anywhere, and neither is the part of you that's asking the question.